MEIP - MEI Pharma

-

$undefined

N/A

(N/A)

MEI Pharma NasdaqCM:MEIP MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Location: 9920 Pacific Heights Blvd., Suite 250, San Diego, CA, 92121, United States | Website: https://meipharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-5.88M

Cash

20.47M

Avg Qtr Burn

-9.096M

Short % of Float

0.04%

Insider Ownership

1.31%

Institutional Own.

40.16%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ME-344 (Mitochondrial Inhibitor) + bevacizumab Details
Cancer, Solid tumor/s, Colorectal cancer

Phase 1b

Update

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Voruciclib (CDK Inhibitor) +/- venetoclax Details
B-cell malignancies, Acute myeloid leukemia, Cancer

Failed

Discontinued